BREAKING: CDC estimates 73% of new coronavirus cases in the U.S. are caused by the Omicron variant, up from 3% last week
Lenzilumab is variant agnostic. Virtually all currently authorized mAbs are ineffective against Omicron. A lenzilumab EUA for this winter makes so much sense.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.